Research & Publications

Access peer-reviewed articles and publications from our data experts and customers who are utilizing Inovalon data to change healthcare.

Filter

January 18, 2023
Peer-Reviewed Article

The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings

Neuenschwander J, Silverstein A, Teigland C, Kumar S, Zeng E, Agiro A, Pottorf J, Peacock WF.
Older patients are at increased risk for hyperkalemia (HK). This study describes the prevalence, recurrence, and clinical and economic burden of HK in Medicare patients admitted to a long-term care (LTC) setting.
January 18, 2023
Peer-Reviewed Article

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease

Soileau M, Pagan F, Fasano A, Rodriguez-Cruz, Yan C, Gupta N, Teigland C, Pulungan Z, Schinkel J, Kandukuri P, Ladhani O, Siddiqui M
Complex polypharmacy regimens to manage persistent motor fluctuations result in significant pill burden for patients with advanced Parkinson’s disease (APD). This study evaluated the effectiveness of carbidopa/levodopa enteral suspension (CLES) and deep brain stimulation (DBS) on reducing pill burden in APD patients.
December 23, 2022
Insights

Differences Between COPD Patients Prescribed Revefenacin and Tiotropium Bromide Post-Hospitalization

This real-world evidence study examined demographic and clinical characteristic differences between COPD patients prescribed revefenacin or tiotropium bromide following a COPD hospitalization using two observational claims databases.
December 13, 2022
Presentation

Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US

Chihara D, Liao L, Tkacz J, Lewing B, Franco A, Kilgore K, Nastoupil L, Chen L
The aim of the study was to examine the outcomes and economic impact among older patients with DLBCL receiving CAR T-cell therapy in a real-world setting in the United States.
November 10, 2022
Presentation

Treatment persistence in first-line biologic and targeted synthetic DMARD users with dual-seropositive RA in the Medicare Population

Sparks J, Zheng H, Schwartz T, Park SH, Norris K, Patel V, Robinson S, Witstock K, Khaychuk V, Silverstein A
The results of this study were presented at the American College of Rhuematology Convergence.
May 15, 2022
Presentation

Treatment Patterns in Patients Newly Diagnosed with Schizophrenia with Commercial Versus Medicaid Insurance Coverage

Teigland C, Kim S, Mohammadi I, Agatep B, Boskovic DH
Schizophrenia is a serious mental disorder that requires lifelong treatment. Early treatment can help get symptoms under control before serious complications develop (e.g., suicide, anxiety disorder, aggressive behavior, depression, alcohol/drug abuse, inability to work, financial and health/medical problems). This research evaluated treatment patterns in patients newly diagnosed with schizophrenia in two populations with commercial versus Medicaid insurance.
May 15, 2022
Presentation

Risk Factors for Recurrences of Clostridioides Difficile Infection in the Medicare Population Age 65+ Years

Amin A, Guo A, Teigland C, Mohammadi I, Schablik J, Reveles K
Clostridioides difficile infection (CDI) recurrences are associated with substantial clinical and economic burden including high mortality and high hospitalization cost. We analyzed recently available 100% Medicare Fee-for-Service (FFS) claims to assess recurrence and identify risk factors for patients experiencing 1, 2, and 3+ recurrences of CDI (rCDI) to inform CDI patient management.
May 15, 2022
Presentation

Contemporary Total Cost of Care Among Medicare Patients with Primary and Recurrent Clostridioides Difficile Infection

Amin A, Guo A, Teigland C, Mohammadi I, Schablik J, Reveles K
We evaluated mortality and total healthcare costs among contemporary Medicare patients with primary CDI (pCDI) and recurrent CDI (rCDI), as well as the main drivers of the costs.